Syntara (ASX:SNT) Accounts Payable & Accrued Expense : A$4.23 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Accounts Payable & Accrued Expense?

Syntara's quarterly accounts payable & accrued expense increased from Dec. 2022 (A$3.15 Mil) to Jun. 2023 (A$3.78 Mil) and increased from Jun. 2023 (A$3.78 Mil) to Dec. 2023 (A$4.23 Mil).

Syntara's annual accounts payable & accrued expense declined from Jun. 2021 (A$3.77 Mil) to Jun. 2022 (A$2.70 Mil) but then increased from Jun. 2022 (A$2.70 Mil) to Jun. 2023 (A$3.78 Mil).

Syntara Accounts Payable & Accrued Expense Historical Data

The historical data trend for Syntara's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Accounts Payable & Accrued Expense Chart

Syntara Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

4.83

3.48

3.77

2.70

3.78

Syntara Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															4.29	2.70	3.15	3.78	4.23

Syntara Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Syntara (ASX:SNT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.